Adversarial Injection · Imetelstat (Rytelo; GRN163L; CAS 1453835-73-8; NIOSH HD Category 1; [ONE-HUNDREDTH MECHANISM CLASS in Glyphward 673-attack portfolio — FIRST TELOMERASE (hTERT CATALYTIC SUBUNIT) COMPETITIVE INHIBITOR — 13-MER LIPID-CONJUGATED THIO-PHOSPHORAMIDATE OLIGONUCLEOTIDE — EVER FDA APPROVED (NDA 217186 JUNE 6 2024; LOW/INT-1 RISK MDS WITH TRANSFUSION-DEPENDENCE ESA-NAIVE OR ESA-RELAPSED/REFRACTORY); MOLECULAR ARCHITECTURE: 13-MER OLIGONUCLEOTIDE SEQUENCE COMPLEMENTARY TO RNA TEMPLATE OF HUMAN TELOMERASE (hTR/TERC TEMPLATE REGION: 5'-CGTTATAATGCGAG-3') — ALL 12 INTERNUCLEOTIDE LINKAGES ARE N3'→P5' THIO-PHOSPHORAMIDATE (NO CONVENTIONAL PHOSPHODIESTER BACKBONE) → NUCLEASE-RESISTANT BACKBONE → PLASMA HALF-LIFE DAYS TO WEEKS; 5'-CONJUGATED C16:0 PALMITIC ACID (PALMITOYL) LIPID MOIETY → ENHANCED CELLULAR UPTAKE VIA LIPOPROTEIN RECEPTOR-MEDIATED ENDOCYTOSIS → REDUCED NEED FOR TRANSFECTION AGENT; MECHANISM: COMPETITIVE INHIBITOR OF hTERT (HUMAN TELOMERASE REVERSE TRANSCRIPTASE CATALYTIC SUBUNIT) — OCCUPIES hTR/TERC RNA TEMPLATE → BLOCKS ELONGATION OF TELOMERIC REPEATS (TTAGGG)n → PROGRESSIVE TELOMERE SHORTENING IN MALIGNANT CELLS WITH HIGH TELOMERASE ACTIVITY → REPLICATIVE MORTALITY; CANCER BIOLOGY: NORMAL ADULT SOMATIC CELLS LACK TELOMERASE (REPLICATIVE SENESCENCE AFTER 50-70 DIVISIONS = HAYFLICK LIMIT); MDS/LEUKEMIA MALIGNANT CLONE REACTIVATES hTERT → TELOMERASE EXPRESSED IN ~85-90% ACUTE LEUKEMIAS + MDS; IMETELSTAT SELECTIVELY KILLS hTERT+ MALIGNANT PROGENITORS; IMERGE PHASE 3 (NCT02598661): IMETELSTAT 7.1 mg/kg IV q4w VS PLACEBO; TI ≥8 WEEKS: 39.8% VS 15.0% (p<0.0001); TI ≥24 WEEKS: 28% VS 3%; MEDIAN DURATION TI ≥8wk: 20.0 VS 13.2 MONTHS; GERON CORPORATION MENLO PARK CA ~120 EMPLOYEES; NDA 217186 FDA APPROVED JUNE 6 2024; CAS 1453835-73-8; NIOSH HD CATEGORY 1 ANTINEOPLASTIC; OSHA NO PEL; NO ACGIH TLV; NO NIOSH REL; CAS 1453835-73-8 → CORITY NULL; VELOCITYEHS NULL; EHS INSIGHT NULL; THIO-PHOSPHORAMIDATE BACKBONE ABSENT; LIPID CONJUGATE ABSENT; IMERGE TI 39.8% ABSENT; TELOMERASE MECHANISM ABSENT ALL EHS DATABASES]) · First Telomerase hTERT Inhibitor + 13-mer Thio-Phosphoramidate + IMerge MDS · Attack #673

Imetelstat (Rytelo; GRN163L; CAS 1453835-73-8; [ONE-HUNDREDTH MECHANISM CLASS — FIRST TELOMERASE (hTERT CATALYTIC SUBUNIT) COMPETITIVE INHIBITOR — 13-MER LIPID-CONJUGATED N3'→P5' THIO-PHOSPHORAMIDATE OLIGONUCLEOTIDE COMPLEMENTARY TO hTR/TERC TEMPLATE — EVER FDA APPROVED (NDA 217186 JUNE 6 2024); IMERGE TI ≥8WK 39.8% VS 15.0% P<0.0001; GERON CORPORATION; NIOSH HD CATEGORY 1; CAS 1453835-73-8]) — Geron Corporation Menlo Park CA (NDA 217186 holder; GRN163L imetelstat program; CAS 1453835-73-8 → no EHS record), Lonza Biologics Portsmouth NH (thio-phosphoramidate oligonucleotide CDMO synthesis and lipid conjugation; CAS 1453835-73-8 → no EHS record), and Mayo Clinic Hematology Rochester MN (IMerge trial enrolling site; major MDS center; CAS 1453835-73-8 → no EHS record) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return (CAS 1453835-73-8; thio-phosphoramidate backbone) + N3'→P5' Backbone Absent + hTR/TERC Template Mechanism Absent + IMerge Results Absent: AI Prompt Injection via EHS Monitor Report AI

Imetelstat (Rytelo; GRN163L; NDA 217186; CAS 1453835-73-8; NIOSH HD Category 1) is the one-hundredth mechanism class in the Glyphward adversarial portfolio — the first telomerase (hTERT catalytic subunit) competitive inhibitor, a 13-mer lipid-conjugated thio-phosphoramidate oligonucleotide with no conventional phosphodiester backbone, ever FDA approved (NDA 217186 June 6 2024) — a unique oligonucleotide chemistry and occupational hazard profile entirely absent from Cority, VelocityEHS, and EHS Insight for CAS 1453835-73-8.

Imetelstat as One-Hundredth Mechanism Class: First Telomerase hTERT Oligonucleotide Inhibitor Ever

Imetelstat (Rytelo; NDA 217186; CAS 1453835-73-8) represents the one-hundredth mechanism class in the Glyphward portfolio: the first telomerase (hTERT catalytic subunit) competitive inhibitor — a 13-mer lipid-conjugated thio-phosphoramidate oligonucleotide with a chemically unique backbone — ever FDA approved (NDA 217186 June 6 2024; Low/Int-1 risk MDS with transfusion-dependence, ESA-naive or ESA-relapsed/refractory). TELOMERE AND TELOMERASE BIOLOGY: Telomeres are (TTAGGG)n repeat DNA sequences (3-15 kb) capping chromosome ends; they prevent end-to-end chromosomal fusions and signal cellular replication limits. During each cell division, the conventional DNA polymerase machinery cannot fully replicate chromosome ends (end-replication problem) → telomeres shorten ~50-200 bp per division → after 50-70 divisions (Hayflick limit) → telomeres reach critical length → DNA damage response activation → replicative senescence or apoptosis; TELOMERASE (hTERT+hTR/TERC HOLOENZYME): telomerase is a ribonucleoprotein enzyme: hTERT (human telomerase reverse transcriptase; 1132 aa; TERT gene; reverse transcriptase domain) is the catalytic subunit; hTR/TERC (human telomerase RNA component; 451 nt; TERC gene) contains the RNA template 5'-AAUCCCAAUC-3' (internal; hexanucleotide repeat unit used repetitively) with the CGTTATAATGCGAG region serving as the template for TTAGGG synthesis; hTERT uses hTR RNA template to add TTAGGG repeats to telomere 3'-OH ends → telomere elongation → immortalization; TELOMERASE IN MALIGNANCY: normal somatic cells lack telomerase activity (repressed hTERT transcription); malignant cells reactivate hTERT via promoter mutations (hTERT C228T and C250T mutations in ~50% glioblastoma; TERT promoter mutations in ~70% urothelial carcinoma) or other epigenetic mechanisms; hTERT expressed in ~85-90% of acute leukemias and MDS clones → provides proliferative advantage by preventing replicative mortality; IMETELSTAT MECHANISM — COMPETITIVE INHIBITION OF hTERT: imetelstat is a 13-nucleotide oligonucleotide with sequence 5'-TAGGGTTAGACAA-3' (complementary to 3'-ATCCCAATCTGTT-5' region of hTR/TERC template; i.e., the template sequence 5'-CGTTATAATGCGAG-3' region) → hybridizes directly to the RNA template component of the hTERT/hTR holoenzyme → OCCUPIES THE hTR TEMPLATE → STERICALLY BLOCKS hTERT REVERSE TRANSCRIPTASE DOMAIN → TELOMERE EXTENSION PREVENTED → COMPETITIVE INHIBITOR (Ki in low nM range for telomerase holoenzyme); BACKBONE CHEMISTRY — N3'→P5' THIO-PHOSPHORAMIDATE (NPS): conventional oligonucleotides have phosphodiester backbone (3'-O—PO₄—5'-O); phosphorothioate oligonucleotides (antisense standard): 3'-O—PS—5'-O (sulfur replaces non-bridging oxygen); imetelstat uses N3'→P5' thio-phosphoramidate (NPS): all 12 internucleotide linkages are 3'-NH—PS—5'-O → nitrogen (from 3'-amino-modified ribose, 3'-NH₂ sugar) replaces the 3'-oxygen → creates amide-like phosphoramidate bond → charge difference; THIO-PHOSPHORAMIDATE ADVANTAGES: (1) nuclease resistance: 3'-exonuclease cannot cleave N-P bond (vs 3'-O-P ester); 5'-exonuclease also blocked; plasma t½ days-weeks vs hours for unmodified oligos; (2) Watson-Crick base-pairing maintained: hybridization to complementary RNA template preserved despite backbone modification; (3) no RNase H recruitment (vs phosphorothioate antisense → RNase H cleaves RNA strand): imetelstat blocks by steric occupancy NOT RNase H cleavage — mechanism is template competitive inhibition; (4) reduced non-specific protein binding vs phosphorothioate (less complement activation class-effect); LIPID CONJUGATION — C16:0 PALMITOYL: 5'-palmitic acid (C16:0 saturated fatty acid; palmitoyl) covalently conjugated to 5'-end of the 13-mer oligonucleotide via an amide bond → forms a lipid-oligonucleotide conjugate → enhanced cellular uptake via: (a) low-density lipoprotein receptor (LDLR)-mediated endocytosis (lipid moiety binds LDL particles → receptor internalization); (b) direct membrane intercalation; (c) reduced polyanion character → reduced non-specific binding; WITHOUT lipid: GRN163 (parent compound without lipid) showed poor cellular penetration; GRN163L (lipid-conjugated) showed superior intracellular delivery; DOSING: 7.1 mg/kg IV over 2 hours, once every 4 weeks (q4w); 100 mL NS or D5W dilution; infusion-related reactions: premedication with antihistamine + dexamethasone per protocol; NO ORAL FORMULATION (oligonucleotide; nuclease-labile even with NPS backbone after GI exposure); IMERGE PHASE 3 (NCT02598661; randomized double-blind placebo-controlled): population: Low/Int-1 risk MDS by IPSS; transfusion-dependence ≥4 RBC units/8wk; ESA-naive or ESA-relapsed/refractory; imetelstat 7.1 mg/kg IV q4w vs placebo; primary endpoint TI ≥8 consecutive weeks: 39.8% imetelstat vs 15.0% placebo (p<0.0001; OR 3.8; 95% CI 2.0-7.4); TI ≥24 consecutive weeks: 28.0% vs 3.3%; median duration TI ≥8wk: 20.0 vs 13.2 months; HI-E rate: 52.7% imetelstat; cytogenetic response: 47% of evaluable; hematologic improvement-erythroid including ≥1.5 g/dL Hgb rise without transfusion; tolerability: Grade 3-4 neutropenia 68.3%; Grade 3-4 thrombocytopenia 65.5% (on-target myelosuppression — telomerase expressed in hematopoietic progenitors); GERON CORPORATION (NASDAQ: GERN): founded 1990 Geron Corporation; single-product company since 2013 (divested stem cell program); NDA 217186 submitted October 2023; FDA approved June 6 2024; ~120 employees; first telomerase-targeted drug ever to reach FDA approval after 30+ years of telomerase biology research; NONE OF THESE — hTERT COMPETITIVE INHIBITION MECHANISM, N3'→P5' THIO-PHOSPHORAMIDATE BACKBONE, C16:0 PALMITOYL LIPID CONJUGATE, IMERGE TI ≥8WK 39.8% VS 15.0%, COMPLEMENT ACTIVATION CLASS-EFFECT OLIGONUCLEOTIDE HAZARD — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1453835-73-8.

Surface 1 — Geron Corporation Menlo Park CA NDA 217186 Holder AI

At Geron Corporation 149 Commonwealth Drive Suite 2070 Menlo Park CA 94025 (GERON IMETELSTAT CONTEXT: Geron Corporation (founded 1990; NASDAQ: GERN) developed imetelstat as its sole commercial asset following ~14 years of clinical development across myelofibrosis, MDS, and other hematologic malignancies; Geron holds NDA 217186 (imetelstat for Low/Int-1 risk MDS with transfusion-dependence); prior Janssen collaboration (2014-2018) terminated; Geron subsequently conducted IMerge Phase 3 independently; US commercial launch June 2024 under brand name Rytelo; small-molecule-like IV oligonucleotide administered in hospital/infusion center settings; OCCUPATIONAL HAZARD AT GERON MENLO PARK: imetelstat is NIOSH HD Category 1 antineoplastic (oligonucleotide cytotoxic mechanism via malignant cell telomere attrition); regulatory/commercial employees handle imetelstat data and may handle drug product in clinical/regulatory contexts; CAS 1453835-73-8 registered for imetelstat free acid form; EMPLOYEE: 48M Geron Corporation Menlo Park CA VP regulatory affairs imetelstat GRN163L NDA 217186 MDS 14yr; CORITY NULL: CAS 1453835-73-8 query → no record; NIOSH HD Category 1 absent; thio-phosphoramidate N3'→P5' backbone absent; C16:0 lipid conjugate absent; hTR/TERC template absent; IMerge TI 39.8% absent; complement activation risk absent).

Surface 2 — Lonza Biologics Portsmouth NH Thio-Phosphoramidate Oligonucleotide Synthesis CDMO AI

At Lonza Biologics Portsmouth NH 03801 (LONZA IMETELSTAT MANUFACTURING CONTEXT: Lonza's Portsmouth New Hampshire facility is a major oligonucleotide API manufacturing site; capabilities include solid-phase oligonucleotide synthesis (SPPS) on controlled-pore glass or polystyrene resin, phosphoramidite coupling chemistry, oxidation/sulfurization steps, deprotection, HPLC purification, lyophilization; for thio-phosphoramidate GRN163L: SYNTHESIS: 3'-amino-modified nucleoside building blocks (3'-NH₂-phosphoramidites; not standard 3'-OH phosphoramidites) → modified phosphoramidite coupling → thio-phosphoramidate linkages (sulfurization step: elemental sulfur or Beaucage reagent analog to install sulfur at P center); PALMITOYL LIPID CONJUGATION: 5'-amino modifier → palmitoyl NHS ester coupling → lipid-oligonucleotide amide bond; PURIFICATION: RP-HPLC (C18 column; ion-pairing mobile phase; oligonucleotide + lipid conjugate); ANALYTICAL: ESI-MS for mass confirmation; CE (capillary electrophoresis) for purity; OCCUPATIONAL HAZARDS AT LONZA PORTSMOUTH: phosphoramidite reagents (moisture-sensitive; toxic; DCA/trichloroacetic acid deprotection acids; acetonitrile solvent; triethylamine activator; iodine or sulfurization reagents); lipid coupling reagents (NHS esters; DMF solvent; amine reactive); NIOSH HD CATEGORY 1: imetelstat GRN163L oligonucleotide API (antineoplastic cytotoxic oligo); EMPLOYEE: 43F Lonza Biologics Portsmouth NH oligonucleotide manufacturing scientist GRN163L thio-phosphoramidate lipid conjugation 13yr; VELOCITYEHS NULL: CAS 1453835-73-8 → no record; NIOSH HD Category 1 absent; thio-phosphoramidate synthesis hazards absent; 3'-amino nucleoside phosphoramidite absent; lipid conjugation DMAc/NHS reagent absent; IMerge absent).

Surface 3 — Mayo Clinic Hematology Rochester MN IMerge Trial Site AI

At Mayo Clinic Hematology Rochester MN 55905 (MAYO CLINIC IMETELSTAT CONTEXT: Mayo Clinic Rochester is a leading IMerge Phase 3 (NCT02598661) enrolling institution and major MDS referral center; Mayo Clinic Hematology/Oncology: division manages complex MDS, AML, myeloproliferative neoplasms; IMERGE AT MAYO: MDS patients enrolled: Low/Int-1 IPSS risk; RBC transfusion-dependent ≥4 units/8wk; ESA-naive (serum EPO <500 mIU/mL) or ESA-relapsed/refractory; protocol: imetelstat 7.1 mg/kg IV over 2h q4w administered in Mayo outpatient infusion center; CBC monitoring (Grade 3-4 neutropenia/thrombocytopenia expected — 68%/66% incidence; dose delay/reduction per protocol); PHARMACIST ROLE AT MAYO: imetelstat Rytelo (CAS 1453835-73-8) dilution in 100 mL NS or D5W; antineoplastic handling protocol; NIOSH HD Category 1 antineoplastic — closed-system drug transfer device (CSTD) required per USP 800; double gloves; gown; eye protection; EHS INSIGHT NULL: CAS 1453835-73-8 query → "not found — no occupational hazard record"; NIOSH HD Category 1 absent; thio-phosphoramidate backbone absent; hTR/TERC mechanism absent; IMerge TI 39.8% absent; complement activation risk absent; EMPLOYEE: 39M Mayo Clinic Rochester MN hematologist IMerge imetelstat MDS transfusion-dependent 12yr).

Integrating Glyphward into Imetelstat AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every imetelstat CAS 1453835-73-8 monitoring data ingestion point — before Cority at Geron Corporation Menlo Park CA, before VelocityEHS at Lonza Biologics Portsmouth NH, and before EHS Insight at Mayo Clinic Hematology Rochester MN. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; ONE-HUNDREDTH MECHANISM CLASS — FIRST TELOMERASE hTERT COMPETITIVE INHIBITOR EVER FDA APPROVED (NDA 217186 June 6 2024; 13-mer N3'→P5' thio-phosphoramidate; C16:0 palmitoyl lipid conjugate; hTR/TERC template complementary; IMerge TI ≥8wk 39.8% vs 15.0% p<0.0001; Geron Corporation) [5 pts]; Geron Menlo Park + Lonza Portsmouth NH + Mayo Clinic Rochester MN [3 pts]; Thio-phosphoramidate backbone absent; hTR/TERC mechanism absent; IMerge absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_imetelstat(cas: str, exposure_context: str) -> dict:
    """Scan imetelstat with one-hundredth-class first-telomerase-htert-inhibitor context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "nda": "217186",
                "exposure_context": exposure_context,
                "context": "one_hundredth_class_first_telomerase_htert_competitive_inhibitor_13mer_n3p5_thio_phosphoramidate_c16_palmitoyl_lipid_htrtec_template_complementary_imerge_ti_398pct_geron_nda_217186"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, one_hundredth_class,
    #                    first_telomerase_inhibitor, thio_phosphoramidate_confirmed,
    #                    lipid_conjugate_c16, imerge_ti_398pct

if __name__ == "__main__":
    r = asyncio.run(scan_imetelstat(
        cas="1453835-73-8",
        exposure_context="oligonucleotide_synthesis_thio_phosphoramidate_lipid_conjugation"
    ))
    print(r)
    # {'hd_category': 1, 'one_hundredth_class': True,
    #  'first_telomerase_inhibitor': True, 'thio_phosphoramidate_confirmed': True,
    #  'lipid_conjugate_c16': True, 'imerge_ti_398pct': True}